Ripple Therapeutics Corporation

Other

Baylis Medical Company Inc.

Hans Christian Fischer

Ian Charles Parrag

Dimitra Louka

Wendy Alison Naimark

Matthew Alexander John Statham

Kyle Giovanni Battiston

J Paul Santerre

Leonard Pinchuk

John Paul Urbanski

Roseita Esfand

Yun Uhm

Warren Chan

Eli B Nichols

Sawitra Mardyani

Wen Jiang

Jared A Demorat

Robert William Henson

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Ocular inserts comprising a covalently linked steroid dimer

Provided herein are needle assemblies for intravitreal injection of an implant into an eye of a patient through an unsheathed state and a sheathed state. Such needle assemblies are precise and accurate for proper treatment and prevent further damage to the eye.

Intravitreal injector

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Dexamethasone prodrug compositions and uses thereof

Methods and apparatus are disclosed for a catheter having a side-port, through which a device, for example, a wire, may be advanced, and a vestibule in the outer surface of the catheter at the distal edge of the side-port. The vestibule is operable for providing a gap between the catheter body and a distal tip of the device positioned through the side-port whereby the vestibule facilitates advancement of the devicethrough the side-port and through tissue towards a desired trajectory. In examples wherein the device is a wire having a distal tip electrode, energy may be delivered to a tissue adjacent the side-port, while avoiding damage to a wall of the catheter body.

Side-port catheter

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Glass formulations and uses thereof

A method for manufacturing powdered quantum dots comprising the steps of: a) reacting quantum dots comprising a core, a cap and a first ligand associated with the outer surfaces thereof with a second ligand, the second ligand displacing the first ligand and attaching to the outer surfaces of the quantum dots, b) isolating the quantum dots having the attached second ligand from the reaction mixture, c) reacting the isolated quantum dots having the attached second ligand with a small organic molecule whereby the small organic molecule attaches to the second ligand, d) reacting the quantum dots having the attached small organic molecule with a cross-linking agent to cross-link the small organic molecule attached to the second ligand with an adjacent second ligand attached to the surfaces of the quantum dots, e) isolating the quantum dots formed in step (d); and f) drying the isolated quantum dots to form powdered quantum dots. The invention includes the quantum dots.

Stable, water-soluble quantum dot, method of preparation and conjugates thereof

Growing community of inventors

Toronto, Canada

Hans Christian Fischer